Overview

Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Status:
Not yet recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy of combination of palbociclib, trastuzumab and lapatinib with fulvestrant in ER positiveļ¼ŒHER2-positive breast cancer patients with brain metastasis.
Phase:
Phase 2
Details
Lead Sponsor:
wang shusen
Treatments:
Fulvestrant
Lapatinib
Palbociclib
Trastuzumab